Skip to main content
. 2022 Feb 16;13:814429. doi: 10.3389/fimmu.2022.814429

Figure 2.

Figure 2

Network of treatment comparisons for adverse events. The size of the circles corresponds to the total number of people. Direct comparable treatments are connected with a line. ADA, adalimumab; + D, plus DMARD; CZP, certolizumab; ETA, etanercept; GOL, golimumab; INF, infliximab; PBO, placebo; DMARD, disease-modifying anti-rheumatic drugs.